Starpharma has never been in a better place fundamentally, page-20

I can't disagree with @col69
This Viraleeze product is a practice run for bigger and better things, along with Vivagel/Fleurstat. Management have demonstrated poor capability, both in dealing with marketing and shareholders. I believe the science for DEP is great, and that is why I am in this stock. I've recently bought more presuming tax loss selling - I tend to trade some - not every effort a victory.

Why aren't we provided with concrete metrics for reviewing performance on both Viraleeze and Vivagel products - rather than hot air - i.e. receipts or revenues?

Might be having a good think before voting at the AGM. If the CEO is getting any bonuses or lotto tickets for this poor performance I will be even more unimpressed. I suspect there is a lot of low hanging fruit left on the tree regarding DEP costs etc, based on how Viraleeze has been mismanaged. I don't believe a good plan has been created for Viraleeze, let alone executed. Maybe the product is a marketing based product (rather than something that actually works outside a lab).

To be balanced I do acknowledge that the Viraleeze opportunity was perceived and seized upon to get the product out in a hurry. Maybe some people are capable of noticing opportunities, but need somebody "nuts and bolts" to put the pieces together.